TACH101 Clinical Trial

Tachyon is currently conducting a Phase 1 open-label clinical study evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of TACH101, a first-in-class inhibitor of KDM4, an epigenetic regulator, for the treatment of patients with advanced solid tumors. The study is underway in several clinical centers in the United States.

For detailed information on the ongoing Phase 1 trial, please visit: clinicaltrials.gov.

Tachyon’s Commitment to Diversity

Expanded Access Policy (EAP)